Skip to main content

H.R. 2087

Introduced

Drug Price Transparency Act

Introduced 4/4/2019•116th Congress•House

Latest Action

Subcommittee Hearings Held.

5/21/2019 • House

Summary

Drug Price Transparency Act

This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

Introduced in House • 4/4/2019

Enter your district to see how this bill affects your community
-

Topics & Subjects

Policy Area: Health
Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightConsumer affairsHealth care costs and insuranceHealth information and medical recordsInsurance industry and regulationMedicarePrescription drugsRetail and wholesale trades

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (2)

Party Breakdown

1
Democrats
1
Republicans
0
Independents

Sponsor

R[
Rep. Doggett, Lloyd [D-TX-35]

Democrat • TX-35

Sponsored 4/4/2019

Cosponsors (1)

R[
Rep. Buchanan, Vern [R-FL-16]

R-FL-16

Joined 4/4/2019